Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Ulta Beauty (ULTA), and emphasizes the importance of using these recommendations in conjunction with other analytical tools for making investment decisions [1][5]. Group 1: Brokerage Recommendations - Ulta Beauty has an average brokerage recommendation (ABR) of 1.83, indicating a consensus between Strong Buy and Buy, based on recommendations from 26 brokerage firms [2]. - Out of the 26 recommendations, 15 are classified as Strong Buy, and 2 as Buy, which represent 57.7% and 7.7% of all recommendations respectively [2]. Group 2: Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations may not be advisable, as studies indicate they often fail to guide investors effectively towards stocks with high potential for price appreciation [5]. - Brokerage analysts tend to exhibit a positive bias in their ratings due to the vested interests of their firms, leading to a disproportionate number of favorable ratings compared to negative ones [6][11]. Group 3: Zacks Rank as an Alternative - The Zacks Rank, which classifies stocks from Strong Buy to Strong Sell based on earnings estimate revisions, is presented as a more reliable indicator of near-term price performance compared to ABR [8][12]. - The Zacks Rank is updated more frequently and reflects changes in earnings estimates, making it a timely tool for predicting future price movements [13]. Group 4: Current Earnings Estimates for Ulta - The Zacks Consensus Estimate for Ulta has increased by 0.1% over the past month to $25.52, indicating growing optimism among analysts regarding the company's earnings prospects [14]. - The recent changes in consensus estimates have contributed to Ulta receiving a Zacks Rank of 1 (Strong Buy), suggesting a favorable outlook for the stock [15].

Core Viewpoint - Sallie Mae (SLM) is expected to report quarterly earnings of $0.95 per share, reflecting a 90% increase year-over-year, with revenues projected at $378.46 million, a 4.5% increase from the previous year [1]. Group 1: Earnings and Revenue Estimates - The consensus EPS estimate for the quarter has been revised downward by 12.5% over the past 30 days, indicating a collective reassessment by analysts [2]. - Analysts predict 'Net Interest Margin' to reach 5.2%, up from 4.9% in the same quarter last year [5]. - The consensus estimate for 'Net Interest Income' is $378.46 million, compared to $362.19 million reported in the same quarter of the previous year [5]. Group 2: Other Income Metrics - 'Other income' is expected to be $33.35 million, an increase from $27.71 million in the same quarter last year [6]. - The consensus for 'Total Non-Interest Income' is projected at $56.99 million, significantly higher than the $27.78 million reported in the same quarter last year [6]. Group 3: Market Performance - Shares of Sallie Mae have remained unchanged over the past month, contrasting with a +2% increase in the Zacks S&P 500 composite [6]. - Sallie Mae holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance relative to the overall market in the near future [6].

Core Viewpoint - Atlantic Union (AUB) is expected to report quarterly earnings of $0.86 per share, reflecting a 28.4% increase year-over-year, with revenues projected at $380.7 million, a 71.3% increase compared to the previous year [1]. Earnings Projections - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2]. Key Financial Metrics - Analysts predict an 'Efficiency Ratio' of 52.5%, down from 59.4% in the same quarter last year [4]. - The 'Net Interest Margin' is expected to reach 3.9%, compared to 3.3% in the same quarter of the previous year [4]. - The estimated 'Average Balance - Total earning assets' is projected at $33.61 billion, up from $22.37 billion in the same quarter last year [5]. - 'Total Non Interest Income' is expected to be $52.85 million, compared to $35.23 million in the same quarter last year [5]. Income Estimates - The consensus for 'Net interest income (FTE)' stands at $327.08 million, significantly higher than the year-ago figure of $187.04 million [6]. - 'Interchange fees, net' are expected to reach $3.99 million, up from $3.34 million year-over-year [6]. - 'Bank owned life insurance income' is projected at $5.07 million, compared to $3.56 million last year [6]. Additional Income Projections - 'Fiduciary and asset management fees' are forecasted to be $18.49 million, compared to $6.93 million in the same quarter last year [7]. - 'Other operating income' is estimated at $4.26 million, up from $3.74 million in the same quarter last year [7]. - 'Service charges on deposit accounts' are expected to reach $12.91 million, compared to $9.83 million last year [8]. - 'Loan-related interest rate swap fees' are projected at $4.31 million, down from $5.08 million year-over-year [8]. Stock Performance - Atlantic Union shares have increased by 4.3% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2% [8].

Core Viewpoint - Penumbra's stock price surged 11.8% to close at $350.49, driven by strong trading volume and positive investor sentiment following the announcement of preliminary financial results for Q4 and full year 2025 [1][2]. Financial Performance - Q4 2025 revenue is projected to be between $383.0 million and $384.8 million, indicating a year-over-year growth of approximately 21.4% to 22.0% [2]. - Full year revenue for 2025 is expected to range from $1,401.3 million to $1,403.1 million, reflecting a year-over-year growth of about 17.3% to 17.5% [2]. - The upcoming quarterly earnings are anticipated to be $1.12 per share, representing a year-over-year increase of 15.5%, with revenues expected at $362.5 million, up 14.9% from the previous year [3]. Market Sentiment - Investor optimism is bolstered by Boston Scientific's agreement to acquire Penumbra at $374 per share, contributing to the stock's recent price increase [2]. - The consensus EPS estimate for Penumbra has been revised slightly higher over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. Industry Context - Penumbra operates within the Zacks Medical - Instruments industry, where another company, Masimo, has shown a modest increase of 1.1% in its stock price [4]. - Masimo's EPS estimate has remained unchanged at $1.4, reflecting a year-over-year decline of 22.2%, and it currently holds a Zacks Rank of 4 (Sell) [5].

Company Overview - inTest Corporation (INTT) shares increased by 8.9% to close at $8.72, with notable trading volume exceeding typical levels [1] - The stock has gained 8.5% over the past four weeks, driven by record order growth, backlog expansion, and strong demand in the auto/EV and defense sectors [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.16 per share, reflecting a year-over-year decline of 30.4% [2] - Expected revenues are $31.74 million, down 13.3% from the same quarter last year [2] Earnings Estimate Trends - The consensus EPS estimate for inTest has remained unchanged over the last 30 days, indicating a lack of upward revisions which typically correlate with stock price movements [3] - Monitoring inTest's performance is essential to determine if the recent stock price increase can sustain momentum [3] Industry Context - inTest is part of the Zacks Electronics - Measuring Instruments industry, which includes Keysight (KEYS) [4] - Keysight's stock rose by 2.4% to $214.5, with a 5.5% return over the past month, and it has a consensus EPS estimate of $1.99, representing a 9.3% increase year-over-year [5]

Continental AG (CTTAY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a c ...

Core Viewpoint - Virax Biolabs Group Limited (VRAX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Virax Biolabs reflects an improvement in its earnings outlook, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between earnings estimate revisions and near-term stock movements, making it beneficial for investors to track these revisions [7]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a historical average annual return of +25% for Zacks Rank 1 stocks since 1988 [8]. Specific Earnings Data for Virax Biolabs - For the fiscal year ending March 2026, Virax Biolabs is expected to earn -$0.40 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 60.4% over the past three months [9]. Zacks Rating System Overview - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, with only the top 20% receiving a "Strong Buy" or "Buy" rating [10][11]. - The upgrade of Virax Biolabs to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Core Viewpoint - Hitachi Ltd. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook for its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade suggest an improvement in Hitachi's underlying business, which could lead to an increase in stock price as investors respond positively [5][10]. - The Zacks Consensus Estimate for Hitachi is projected at $1.15 per share for the fiscal year ending March 2026, with a 1.2% increase in estimates over the past three months [8]. Zacks Rating System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10].

Core Viewpoint - Compass, Inc. has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system highlights the strong correlation between changes in earnings estimates and near-term stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling actions [3]. Company Performance and Outlook - The upgrade for Compass reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Over the past three months, the Zacks Consensus Estimate for Compass has increased by 214%, indicating a significant upward revision in earnings expectations [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - Compass's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Core Viewpoint - Frontier Communications has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have a strong correlation with near-term stock price movements [4][6]. - Rising earnings estimates for Frontier Communications suggest an improvement in the company's underlying business, likely leading to increased stock prices [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Performance of Frontier Communications - Analysts have raised their earnings estimates for Frontier Communications, with the Zacks Consensus Estimate increasing by 11.4% over the past three months [8]. - The company is expected to earn -$1.29 per share for the fiscal year ending December 2025, showing no year-over-year change [8].